Key Insights

Highlights

Treatment Research

1 treatments under study, led by Lenalidomide Revlimid And Romidepsin Istodax

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01742793Phase 1Terminated

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

Showing all 1 trials

Research Network

Common Treatments

  • Lenalidomide Revlimid And Romidepsin Istodax1

Active Sponsors

  • Peter MacCallum Cancer Centre, Australia1
  • Yale University1

Top Investigators

Related Conditions

  • Hodgkins Lymphoma1
  • Multiple Myeloma1

Activity Timeline